Interstitial Lung Disease Market Report 2026

The interstitial lung disease market size has grown strongly in recent years. It will grow from $2.09 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of chronic respiratory diseases, increased exposure to occupational and environmental pollutants, advancements in pulmonary imaging techniques, improved awareness of idiopathic pulmonary fibrosis, expansion of specialty pulmonary clinics.

The interstitial lung disease market size is expected to see strong growth in the next few years. It will grow to $3.09 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to growing aging population, rising diagnosis rates of interstitial lung disorders, increasing adoption of targeted anti-fibrotic drugs, expansion of research in novel ild therapies, improved patient screening and monitoring programs. Major trends in the forecast period include increasing emphasis on early and accurate ild diagnosis, growing adoption of anti-fibrotic therapies, rising focus on disease progression management, expansion of multidisciplinary care approaches, improved access to long-term ild treatment.

The growing prevalence of autoimmune disorders is anticipated to drive the expansion of the interstitial lung disease market in the coming years. Autoimmune disorders are conditions in which the immune system mistakenly targets the body’s own healthy tissues and cells. The increasing occurrence of autoimmune disorders contributes to the interstitial lung disease market by raising demand for ILD-related healthcare services, encouraging research and development activities, and supporting advancements in treatment options and patient management. For example, in September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research organization, reported that the estimated number of rheumatoid arthritis cases worldwide is expected to reach 31.7 million by 2050, reflecting a substantial increase over time. Hence, the rising incidence of autoimmune disorders is fueling the growth of the interstitial lung disease market.

Major companies operating in the interstitial lung disease market are concentrating on product launch trends, including innovative therapies for various interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disorder characterized by scarring of lung tissue, resulting in breathing difficulties and reduced oxygen transfer. For example, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a Germany-based biopharmaceutical company, received FDA approval for BI 1015550 therapy for the treatment of idiopathic pulmonary fibrosis. BI 1015550 is an investigational oral therapy that inhibits phosphodiesterase 4B (PDE4B), exhibiting antifibrotic and anti-inflammatory effects aimed at slowing the decline of lung function in idiopathic pulmonary fibrosis (IPF).

In June 2023, Merck & Co., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.3 billion. Through this acquisition, Merck & Co. aimed to strengthen its immunology drug pipeline as it prepares for the loss of exclusivity of some of its top-selling products in the coming years. Prometheus Biosciences Inc. is a US-based biotechnology company developing therapeutic and ancillary diagnostic products for managing immune-mediated disorders, including interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD).

Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceuticals USA Inc., AstraZeneca plc, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Insmed Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health plc, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.

North America was the largest region in the interstitial lung disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interstitial lung disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interstitial lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the interstitial lung disease market by increasing costs of imported pharmaceuticals, active pharmaceutical ingredients, and specialized manufacturing inputs. These impacts are most pronounced in anti-fibrotic and immunosuppressive drug segments, particularly across asia-pacific and europe where reliance on global supply chains is high. Elevated tariffs have raised treatment costs for hospitals and retail pharmacies. However, tariffs are also encouraging domestic drug manufacturing, local sourcing of raw materials, and investments in cost-efficient production, supporting long-term market resilience.

The interstitial lung disease market research report is one of a series of new reports that provides interstitial lung disease market statistics, including interstitial lung disease industry global market size, regional shares, competitors with a interstitial lung disease market share, detailed interstitial lung disease market segments, market trends and opportunities, and any further data you may need to thrive in the interstitial lung disease industry. This interstitial lung disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interstitial lung disease (ILD) encompasses a group of lung disorders that involve the interstitium, the tissue and space surrounding the alveoli in the lungs. The interstitium plays a vital role in preserving lung structure and function, as it provides support for efficient gas exchange between the lungs and the bloodstream.

The primary categories of drugs used to treat interstitial lung disease include oral corticosteroids, immunosuppressive agents, anti-fibrotic therapies, and other medications. Interstitial pneumonia, also referred to as non-infectious interstitial pneumonia, is a form of ILD that involves inflammation of the interstitium, the tissue that surrounds and supports the lung alveoli. These therapies are used to manage conditions such as interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis in both adults and children. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The interstitial lung disease market consists of revenues earned by entities by providing services such as individualized treatment plans and comprehensive support, pulmonary rehabilitation and oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The interstitial lung disease market also includes sales of prednisone, mycophenolate, azathioprine and cyclophosphamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.